Redhill Biopharma - ADR

NASDAQ:RDHL   12:30:50 PM EDT
6.56
-0.05 (-0.76%)
Products

Redhill Biopharma's Opaganib Inhibits Covid-19 Variants In Preclinical Study

Published: 06/28/2021 12:15 GMT
Redhill Biopharma - ADR (RDHL) - Redhill Biopharma's Opaganib Inhibits Covid-19 Variants in Preclinical Study.
Redhill Biopharma - Opaganib Strongly Inhibits Beta (south African) and Gamma (brazilian) Covid-19 Variants, Further Supporting Its Antiviral Activity.
Redhill Biopharma - Opaganib's Dual Antiviral and Anti-inflammatory Approach is Also Expected to Maintain Effect Against the Delta (indian) Variant.
Redhill - Completion of Opaganib's Global Fully Enrolled 475-patient Phase 2/3 Study in Hospitalized Patients With Covid-19 Expected in Coming Weeks.